查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1416334

生技药品合约开发市场报告：2030 年趋势、预测与竞争分析

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

生技药品合约发展趋势及预测

到 2030 年，全球合约生技药品开发市场预计将达到 409 亿美元，2024 年至 2030 年复合年增长率为 11.5%。该市场的主要驱动因素是製药公司的药物开发程序数量不断增加、先进技术的采用不断增加以及新兴国家临床试验的有利环境。全球合约生技药品开发市场的未来看起来充满希望，肿瘤学、免疫学、心血管和血液学市场充满机会。

生技药品合约开发市场洞察

Lucintel 预测，由于越来越多地采用哺乳动物细胞来表达蛋白质，因此在预测期内，哺乳动物将继续占据更大的份额。透过开发具有正确转译后修饰的哺乳动物蛋白质以实现其天然结构，这提供了显着的优势。

肿瘤学将继续成为该市场最大的细分市场，因为治疗需求的不断增长正在推动研发和外包的进一步投资。

由于研发投资不断增加、临床试验需求不断增长以及该地区领先公司的存在，预计北美在整个预测期内仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球合约生技药品开发市场预计将达到 409 亿美元。

Q2.市场成长预测是多少：

A2. 2024 年至 2030 年，全球生技药品合约开发市场预计将以 11.5% 的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动因素是製药公司增加药物开发程序、增加先进技术的采用以及新兴国家有利的临床试验环境。

Q4.市场的主要细分市场是：

A4.生技药品合约开发市场的未来前景看好，在肿瘤学、免疫学、心血管和血液学市场中存在机会。

Q5.市场的主要企业是：

A5. 一些主要的生技药品合约开发公司如下。

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于越来越多地采用哺乳动物细胞进行蛋白质表达，哺乳动物在预测期内将继续占据更大的份额。透过开发具有正确转译后修饰的哺乳动物蛋白质以实现其天然结构，这提供了显着的优势。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于研发投资增加、临床试验需求增加以及该地区领先公司的存在，预计北美仍将是整个预测期内最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球生技药品合约开发市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球生技药品合约开发市场趋势（2018-2023）与预测（2024-2030）
  • 按来源分類的全球生技药品开发市场
    • 微生物
    • 哺乳动物的
    • 其他的
  • 按产品服务分類的全球生技药品合约开发市场
    • 细胞株开发
    • 製程开发
    • 其他的
  • 按疾病适应症分類的全球生技药品合约开发市场
    • 瘤
    • 免疫疾病
    • 心血管疾病
    • 血液疾病
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球生技药品合约开发市场
  • 北美生技药品合约开发市场
  • 欧洲合约生技药品开发市场
  • 亚太生技药品合约开发市场
  • 其他地区生技药品合约开发市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球生技药品合约开发市场成长机会（按来源）
    • 全球生技药品合约开发市场成长机会（依产品服务）
    • 按疾病适应症分類的全球生技药品合约开发市场的成长机会
    • 按地区分類的全球生技药品合约开发市场成长机会
  • 全球生技药品合约开发市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球合约生技药品开发市场的能力
    • 全球合约生技药品开发市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence
简介目录

Biologics Contract Development Trends and Forecast

The future of the global biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets. The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030 with a CAGR of 11.5% from 2024 to 2030. The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

A more than 150-page report is developed to help in your business decisions.

Biologics Contract Development by Segment

The study includes a forecast for the global biologics contract development by source, product service, disease indication, and region.

Biologics Contract Development Market by Source [Shipment Analysis by Value from 2018 to 2030]:

  • Microbial
  • Mammalian
  • Others

Biologics Contract Development Market by Product Service [Shipment Analysis by Value from 2018 to 2030]:

  • Cell Line Development
  • Process Development
  • Others

Biologics Contract Development Market by Disease Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Biologics Contract Development Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Biologics Contract Development Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biologics contract development companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biologics contract development companies profiled in this report include-

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Biologics Contract Development Market Insights

Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Within this market, oncology will remain the largest segment due to growing demand for therapy, which encourages more investments in research and development and outsourcing.

North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Features of the Global Biologics Contract Development Market

Market Size Estimates: Biologics contract development market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biologics contract development market size by source, product service, disease indication, and region in terms of value ($B).

Regional Analysis: Biologics contract development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different sources, product services, disease indication, and regions for the biologics contract development market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biologics contract development market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the biologics contract development market size?

Answer: The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030.

Q2. What is the growth forecast for biologics contract development market?

Answer: The global biologics contract development market is expected to grow with a CAGR of 11.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the biologics contract development market?

Answer: The major drivers for this market are rising number of drug development procedures by pharmaceutical companies, growing adoption of advanced technologies, and favorable environment for clinical trials in the developing countries.

Q4. What are the major segments for biologics contract development market?

Answer: The future of the biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets.

Q5. Who are the key biologics contract development market companies?

Answer: Some of the key biologics contract development companies are as follows:

  • WuXi Biologics
  • Abzena
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • AGC Biologics
  • Thermo Fisher Scientific
  • Curia Global
  • Genscript
  • Bionova Scientific
  • BioXcellence

Q6. Which biologics contract development market segment will be the largest in future?

Answer: Lucintel forecasts that mammalian will remain the larger segment over the forecast period due to increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that delivers a native structure.

Q7. In biologics contract development market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing R&D investments, rising demand of clinical trials, and presence of major players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the biologics contract development market by source (microbial, mammalian, and others), product service (cell line development, process development, and others), disease indication (oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biologics Contract Development Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Biologics Contract Development Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Biologics Contract Development Market by Source
    • 3.3.1: Microbial
    • 3.3.2: Mammalian
    • 3.3.3: Others
  • 3.4: Global Biologics Contract Development Market by Product Service
    • 3.4.1: Cell Line Development
    • 3.4.2: Process Development
    • 3.4.3: Others
  • 3.5: Global Biologics Contract Development Market by Disease Indication
    • 3.5.1: Oncology
    • 3.5.2: Immunological Disorders
    • 3.5.3: Cardiovascular Disorders
    • 3.5.4: Hematological Disorders
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Biologics Contract Development Market by Region
  • 4.2: North American Biologics Contract Development Market
    • 4.2.2: North American Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.3: European Biologics Contract Development Market
    • 4.3.1: European Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.3.2: European Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.4: APAC Biologics Contract Development Market
    • 4.4.1: APAC Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.4.2: APAC Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
  • 4.5: ROW Biologics Contract Development Market
    • 4.5.1: ROW Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
    • 4.5.2: ROW Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Biologics Contract Development Market by Source
    • 6.1.2: Growth Opportunities for the Global Biologics Contract Development Market by Product Service
    • 6.1.3: Growth Opportunities for the Global Biologics Contract Development Market by Disease Indication
    • 6.1.4: Growth Opportunities for the Global Biologics Contract Development Market by Region
  • 6.2: Emerging Trends in the Global Biologics Contract Development Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Biologics Contract Development Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Contract Development Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: WuXi Biologics
  • 7.2: Abzena
  • 7.3: Fujifilm Diosynth Biotechnologies
  • 7.4: KBI Biopharma
  • 7.5: AGC Biologics
  • 7.6: Thermo Fisher Scientific
  • 7.7: Curia Global
  • 7.8: Genscript
  • 7.9: Bionova Scientific
  • 7.10: BioXcellence